Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.
Quote | Alk-Abello A/S ADR (OTCMKTS:AKABY)
Last: | $86.22 |
---|---|
Change Percent: | 1.26% |
Open: | $86.22 |
Close: | $86.22 |
High: | $86.22 |
Low: | $86.22 |
Volume: | 500 |
Last Trade Date Time: | 04/20/2022 04:52:32 pm |
News | Alk-Abello A/S ADR (OTCMKTS:AKABY)
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma - Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have ...
Actress and Entrepreneur JoAnna Garcia Swisher and Husband, Former MLB World Champion Nick Swisher, Join New Campaign to Empower Allergy Sufferers to Take Control of Their Allergies - New survey results reveal 71 percent of U.S. adults have experienced environmental allergy symp...
Message Board Posts | Alk-Abello A/S ADR (OTCMKTS:AKABY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Alk-Abello A/S ADR Company Name:
AKABY Stock Symbol:
OTCMKTS Market:
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma - Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have ...
Actress and Entrepreneur JoAnna Garcia Swisher and Husband, Former MLB World Champion Nick Swisher, Join New Campaign to Empower Allergy Sufferers to Take Control of Their Allergies - New survey results reveal 71 percent of U.S. adults have experienced environmental allergy symp...
ROUND ROCK, Texas , June 17, 2020 /PRNewswire/ -- ALK ( ALKB:DC / OMX:ALK B / AKABY / AKBLF ) a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy...